A multi-centric study on the efficacy of eltrombopag in management of refractory chronic immune thrombocytopenia
Makaleler > Tam Makale · 2019
Yazarlar: Demet Cekdemir, Serkan Guvenc, Fusun Ozdemirkiran, Ali Eser, Tayfur Topts, Vildan Ozkocaman, Handan Haydaroglu Sahin, Esra Ermis Turak, Ramazan Esen, Melda Comert, Güray SAYDAM
Turkish Journal of Hematology, SCI İndekslerine Giren Dergi, Uluslararası, Wos, 2019, cilt 36, ss 230-237
DOI: 10.4274/tjh.galenos.2019.2018.0307
Özet
Objective: The aim of the present study was to evaluate the efficacy and safety of eltrombopag, an oral thrombopoietin receptor agonist, in patients with chronic immune thrombocytopenia (ITP). Materials and Methods: ). Clinical findings, descriptive features, response to treatment, and side effects were recorded. Correlations between descriptive, clinical, and hematological parameters were analyzed. Results: weeks of treatment. As the time required for partial or complete response increased, response to treatment was significantly reduced. The time to reach the maximum platelet levels after treatment was quite variable (1-202 weeks). Notably, the higher the maximum platelet count after eltrombopag treatment, the more likely that side effects would occur. The most common side effects were headache (21.6%), weakness (13.7%), hepatotoxicity (11.8%), and thrombosis (5.9%). Conclusion: Results of the current study imply that eltrombopag is an effective therapeutic option even in elderly patients with chronic ITP. However, patients must be closely monitored for response and side effects during treatment. Since both response and side effects may be variable throughout the follow-up period, patients should be evaluated dynamically, especially in terms of thrombotic risk factors.